

Discovery Report

Patent: EVE-PAT-2026-001 | Organiq Sweden AB

1 - DISCOVERY

QUERY	TYPE 2 auto-scan: Similarity bridge: ibrutinib cabozantinib via LYN, EGFR, RET +7 more
COMPOUND	IBRUTINIB
DISCOVERY SCORE	24.000
ENGINE	DISCOVERY_v1.2
CORPUS VERSION	v20260506-01
GENERATED	2026-05-14T03:00:00.077Z

2 - EVIDENCE

TARGETS	LYN, EGFR, RET, LCK, SRC, HCK, ABL1, PTK6, ABL2, BCR
PATHWAYS	—
EVIDENCE SCORE	0.00
STUDIES	0

X-VAULT EVIDENCE SEAL

SYSTEM	BiohacksAI XVAULT_v1
DISCOVERY ID	disc_T2_cabozantinib_ibrutinib_2acca506
EVENT HASH	fe452332a943b0c2...e2f2dc6e
CHAIN HASH	a7f815df3abe05b4...552be61b
PREV HASH	60c072a34c26885b...b517020f
CORPUS VERSION	v20260506-01
CORPUS ROOT	6178ce3d1b9ff52e...d1c9a225
VAULT INDEX	2976
SEALED AT (UTC)	2026-05-14T03:00:00.110Z

- VERIFICATION

This document is cryptographically sealed by the BiohacksAI X-Vault Evidence Engine. The discovery payload hash and corpus Merkle root can be independently verified.

Verify at: eveverified.com/verify

Verification fingerprint: fe452332a943b0c2...e2f2dc6e

